Kiniksa Pharmaceuticals International, plc
KNSA
Classifica tra le azioni
#2912
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prezzo delle azioni
$82.30
Capitalizzazione di mercato
$6.42B
Variazione (1 giorno)
3.55%
Variazione (1 anno)
111.08%
Paese
GB
Scambia Kiniksa Pharmaceuticals International, plc (KNSA)
Categoria
Healthcare
Rapporto P/B per Kiniksa Pharmaceuticals International, plc (KNSA)
Rapporto P/B al October 2026 TTM: 9.35
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Kiniksa Pharmaceuticals International, plc, il rapporto P/B attuale (TTM) è 9.35. Alla fine del 2023, era pari a 2.80.
Storico del rapporto P/B per Kiniksa Pharmaceuticals International, plc da 2016 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 9.35 | 190.37% |
| 2024 | 3.22 | 15.07% |
| 2023 | 2.80 | -232.57% |
| 2022 | -2.11 | 76.75% |
| 2021 | -1.20 | -43.41% |
| 2020 | -2.11 | 25.79% |
| 2019 | -1.68 | -60.72% |
| 2018 | -4.27 | -39.36% |
| 2017 | -7.05 | -71.32% |
| 2016 | -24.57 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 3.8424 | -58.90% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 17.3539 | 85.61% |
US
|
